Glioblastomas and Temporalis Muscle

Zezhong Ye^{1

2}, Dan Sun³, Joshua S Lin⁴

Affiliations

¹ Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA.
² Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
³ Department of Technology, Tempus AI, Inc, Chicago, Illinois, USA.
⁴ Caruso Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

Zezhong Ye et al. J Magn Reson Imaging. 2025 May.

. 2025 May;61(5):2338-2339.

doi: 10.1002/jmri.29645. Epub 2024 Nov 5.

Zezhong Ye^{1

2}, Dan Sun³, Joshua S Lin⁴

¹ Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA.
² Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
³ Department of Technology, Tempus AI, Inc, Chicago, Illinois, USA.
⁴ Caruso Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

No abstract available

References

1. Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: A Society for Neuro‐Oncology (SNO) and European Society of Neuro‐Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 2020;22:1073‐1113. https://doi.org/10.1093/neuonc/noaa106.
1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17‐48. https://doi.org/10.3322/caac.21763.
1. Ye Z, Price RL, Liu X, et al. Diffusion histology imaging combining diffusion basis spectrum imaging (DBSI) and machine learning improves detection and classification of glioblastoma pathology. Clin Cancer Res 2020;26:5388‐5399. https://doi.org/10.1158/1078-0432.CCR-20-0736.
1. Nayak L, Deangelis LM, Brandes AA, et al. The neurologic assessment in neuro‐oncology (NANO) scale: A tool to assess neurologic function for integration into the response assessment in neuro‐oncology (RANO) criteria. Neuro Oncol 2017;19:625‐635. https://doi.org/10.1093/neuonc/nox029.
1. Aerts HJWL, Velazquez ER, Leijenaar RTH, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006. https://doi.org/10.1038/ncomms5006.